GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. - Test2 - elhamkhani - TriplyDB

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

http://www.wikidata.org/entity/Q30440925

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Neuroplasticity and the next wave of antidepressant strategies Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract MDMA for the treatment of mood disorder: all talk no substance?Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants Antidepressant mechanism of ketamine: perspective from preclinical studies Rats selectively bred for low levels of play-induced 50 kHz vocalizations as a model for autism spectrum disorders: a role for NMDA receptors NMDA receptor modulators: an updated patent review (2013-2014)GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists A brief history of the development of antidepressant drugs: from monoamines to glutamate Affective preclinical modeling of psychiatric disorders: taking imbalanced primal emotional feelings of animals seriously in our search for novel antidepressants Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression Integrative biological analysis for neuropsychopharmacology Conductance of P2X4 purinergic receptor is determined by conformational equilibrium in the transmembrane region The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.Ketamine Infusion Associated with Improved Neurology in a Patient with NMDA Receptor Encephalitis.Experimental medication treatment approaches for depression.IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity.GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Attenuates Cerebral Ischemia Injury In Vivo and Vitro by Differential Modulations of NMDA Receptors Subunit Components at Different Post-Ischemia Stage in Mice Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism Intracranial self-stimulation to evaluate abuse potential of drugs.The IGF-derived tripeptide Gly-Pro-Glu is a weak NMDA receptor agonist Existing and novel biological therapeutics in suicide prevention.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.Investigational drugs for treating major depressive disorder.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.Reduced curvature of ligand-binding domain free-energy surface underlies partial agonism at NMDA receptors.PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13.Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis Presynaptic mechanisms of lead neurotoxicity: effects on vesicular release, vesicle clustering and mitochondria number Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice.Insulin-Like Growth Factor I Produces an Antidepressant-Like Effect and Elicits N-Methyl-D-Aspartate Receptor Independent Long-Term Potentiation of Synaptic Transmission in Medial Prefrontal Cortex and Hippocampus.The Prefrontal Dectin-1/AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-β-Glucan from Maitake.

P2860

Q21129276-5B30EC0F-A52D-441C-A65A-EA9414DF3FBB Q21129480-719039EB-2578-465B-A827-8074C619CBBE Q21132322-27BCAE81-0D84-40DB-A145-425B652CA84C Q21558551-34D37205-429C-4ACD-B3F7-A24E5551F51D Q26782274-E94A09EA-AF7C-4FBC-8EE9-3893F1402115 Q26800231-104DBF61-D710-4843-8E84-6155592142E6 Q26866047-53FF09EF-5FBE-48F5-95B9-138CD7ECEE5A Q26997407-5C7266B9-3866-4BDC-922D-10D7C7B27F4E Q27025974-E918984D-3B2A-47A9-AAB4-5A3EA61F2CF7 Q27028050-23E79FC2-6850-4182-A6A3-716660195F84 Q28068011-B137F39F-D768-4A12-99B4-82115782C6B4 Q28277636-208E9263-71E5-4322-8512-2D30CC9984D3 Q28392635-E1F2308A-B534-4EAA-8285-C2E8A92E9CFB Q28833615-47E15450-08E5-4833-9885-E7E290D8C6FC Q30373328-B0362CFF-D9EB-41C9-8585-5F5C5DCDBB52 Q30491706-AFDEC7E1-8258-4DC0-9FA4-700D253E3C34 Q30595767-C2E6481F-AC65-4CEA-B652-F52C7DA81E98 Q30695515-EF4F39F0-B7E3-434B-9128-841B22D2942A Q33565956-521F8E9B-17B0-49F2-A068-37BC501D43CE Q33635577-29FFE68F-4B9D-49C4-86D5-985AE0277E68 Q33762274-272B9953-2978-48C9-84D1-6A4BBC53705D Q33780749-E2870705-A674-4C34-A1C5-A62923104293 Q33842686-A42EC4D6-1EE0-4748-8C33-E336008386BF Q33845750-8D2DFE8B-A33D-45B5-B764-A3ED51129A94 Q34063244-00E7E385-4D0C-479D-981E-99110D592EB7 Q34085866-087D53F5-7A31-47E6-806D-1BB20EC70D94 Q34330678-04248F04-6D7F-423E-9AB7-0DEEE096609F Q34333515-731A0833-BDD5-4B5D-91D1-0B4E7DBE4EF0 Q34381226-12567EB2-083C-4EB2-888F-10268EEBDE0F Q34512818-531F4E35-4DED-4718-B773-352FD66CD020 Q34519141-4AFE3989-12D3-4C61-9C62-4414AA9A13ED Q34547274-845E0937-6BBF-4B3C-A4A8-082AC5DB4111 Q34661281-AF1E1E7C-D997-403E-BB57-D8526B7FADE8 Q34859877-357A3DDD-1871-403D-9635-CACDAA63D2E9 Q35224315-2B903FA3-197A-4467-AC81-A821C0683CC1 Q35537196-CBCDCEC9-92D8-4295-834F-0F33226C59BD Q35641846-5BC2BB98-D9C6-4A99-9F27-44C20C70DAE4 Q36002723-3D76E1FF-E4AB-46C7-8153-FFFEABD61F25 Q36635639-B6E6884D-B8AA-4192-A8FE-1CD06FD06106 Q37027915-BBA5CC1C-3668-4337-9FEB-A3068F19F49F

P2860

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

http://www.wikidata.org/entity/Q30440925

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@ast

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@en

type

label

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@ast

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@en

prefLabel

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@ast

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@en

P1433

Q30440925-E3640839-C8B5-4EB0-85D0-D93504EC1F05

P1476

Q30440925-50E75957-D505-40C5-9E89-9E226FD31D83

P2093

Q30440925-0190151D-E50E-4F89-9D3B-6B931151516C

Q30440925-0A58F141-074F-4238-9B25-8F74361F8CFA

Q30440925-28046659-3A1F-4A94-93AB-E4B844F7AACE

Q30440925-3F8FFB6A-FC70-4839-ABEC-43BFDFF26447

Q30440925-4B897C2C-5606-49DF-8D80-6ABA51E62B66

Q30440925-57A3AE06-5445-416A-BFCE-66C558F7338B

Q30440925-DBFDD46B-419C-4240-AEC6-C3DD014D8F30

Q30440925-DC49C5D3-C369-41AC-A8CB-61427ADFAEEB

Q30440925-F2F30CC0-2212-4B02-A179-C49D008A52EE

P2860

Q30440925-0282DB40-E6DA-4D1E-B80A-57BC004DD3A6

Q30440925-02DBE248-D732-421A-82D1-F5256FD8D362

Q30440925-0C3224AC-A1E0-477F-B0D8-1FA9D23FECA6

Q30440925-0C49809F-BEBC-4943-ADDE-E311957CB101

Q30440925-13722FD6-E16A-4746-A122-1E9C95009F38

Q30440925-1EDC3304-F98C-4653-91F6-AF3B3409576E

Q30440925-20DFB466-5E20-4CA1-B1A0-82F0221BCE96

Q30440925-2225DB92-34B8-4E5D-85E9-7692F6FAC7A1

Q30440925-23F49CB1-3D44-4DFC-96E4-6E59EC575294

Q30440925-2837CBC8-BCCC-4E43-B8B8-A63987AE5709

P2888

Q30440925-2CD3E9E0-575C-4BF3-BCA5-BAF56FE2A413

P304

Q30440925-0A5DD6BB-8C94-44FA-BD49-9AE460ED9D3E

P31

Q30440925-01334EB3-2C9E-4004-8DC9-50A1D77CE338

P356

Q30440925-134C46E7-7ACB-42BE-BB01-8B13501028D8

P407

Q30440925-C1499B12-8FED-40F4-A8D3-DBDADA9805AF

P433

Q30440925-2CCAD906-FDED-4994-A908-8FFE0B10E5C8

P478

Q30440925-871752A8-7460-4B8C-A060-F36FB3A8F49A

P577

Q30440925-39D79497-35C9-4B44-ABE2-853F47B0E379

P5875

Q30440925-CED7103C-DA1E-4845-B1B2-FE950F23DE94

P6179

Q30440925-D3DFDA54-EE12-49DA-A375-E7644FBDA7F7

P698

Q30440925-3B45501A-F819-4F93-B00E-203933A64487

P932

Q30440925-45E68861-05B9-4287-8C51-1AC0CFFBC2B4

P356

P1433

Neuropsychopharmacology

P1476

GLYX-13, a NMDA receptor glyci ...... ut ketamine-like side effects.

@en

P2093

Amanda L Gross

http://www.w3.org/2001/XMLSchema#string

J David Leander

http://www.w3.org/2001/XMLSchema#string

Jeffrey Burgdorf

http://www.w3.org/2001/XMLSchema#string

Joseph R Moskal

http://www.w3.org/2001/XMLSchema#string

Katherine L Nicholson

http://www.w3.org/2001/XMLSchema#string

Patric K Stanton

http://www.w3.org/2001/XMLSchema#string

Robert L Balster

http://www.w3.org/2001/XMLSchema#string

Roger A Kroes

http://www.w3.org/2001/XMLSchema#string

Xiao-lei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

Memantine for dementia

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants

Glutamate receptor ion channels: structure, regulation, and function

An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones

AMPA receptor trafficking and synaptic plasticity

P2888

P304

729-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2012.246

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234098738

http://www.w3.org/2001/XMLSchema#string

P6179

1015282619

http://www.w3.org/2001/XMLSchema#string

P698

23303054

http://www.w3.org/2001/XMLSchema#string

P932

3671991

http://www.w3.org/2001/XMLSchema#string